

Yung-Hung Luo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4403839/publications.pdf>

Version: 2024-02-01

35
papers

1,469
citations

686830

13
h-index

395343

33
g-index

36
all docs

36
docs citations

36
times ranked

3114
citing authors

#	ARTICLE	IF	CITATIONS
1	A Review of SARS-CoV-2 and the Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2657.	1.8	530
2	Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. <i>Frontiers in Immunology</i> , 2020, 11, 1022.	2.2	263
3	Clinical manifestation and disease progression in COVID-19 infection. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 3-8.	0.6	115
4	5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 1098-1108.	5.1	88
5	RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10592.	1.8	61
6	Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs. <i>Journal of Thoracic Oncology</i> , 2012, 7, 299-305.	0.5	52
7	Oncogenic circRNA C190 Promotes Nonâ€“Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway. <i>Cancer Research</i> , 2022, 82, 75-89.	0.4	48
8	Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers. <i>Cancers</i> , 2020, 12, 1740.	1.7	45
9	PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Nonâ€“Small Cell Lung Cancer Patients with Malignant Pleural Effusion. <i>Journal of Thoracic Oncology</i> , 2018, 13, 447-453.	0.5	38
10	Lung Cancer in Republic of China. <i>Journal of Thoracic Oncology</i> , 2021, 16, 519-527.	0.5	34
11	Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 64.	1.8	19
12	Spectrum of cancer risk among Taiwanese with chronic obstructive pulmonary disease. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1014-1020.	1.0	17
13	Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with nonâ€“small cell lung cancer and brain metastases. <i>Journal of Neurosurgery</i> , 2020, 133, 313-320.	0.9	14
14	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 16122.	1.6	13
15	Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. <i>Targeted Oncology</i> , 2020, 15, 503-512.	1.7	12
16	The Association Between Tumor Epidermal Growth Factor Receptor (EGFR) Mutation and Multiple Primary Malignancies in Patients With Adenocarcinoma of the Lungs. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 147-151.	0.6	11
17	Tratamiento con ribavirina inhalada en el sÃndrome de dificultad respiratoria aguda inducida por virus respiratorio sincitial en el adulto. <i>Archivos De Bronconeumología</i> , 2011, 47, 315-317.	0.4	10
18	Overview of coronavirus disease 2019: Treatment updates and advances. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 805-808.	0.6	10

#	ARTICLE	IF	CITATIONS
19	Efficient and Accurate Extracting of Unstructured EHRs on Cancer Therapy Responses for the Development of RECIST Natural Language Processing Tools: Part I, the Corpus. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 383-391.	1.0	9
20	Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis. <i>Targeted Oncology</i> , 2021, 16, 207-214.	1.7	9
21	Influence of chemotherapy on EGFR mutation status. <i>Translational Lung Cancer Research</i> , 2013, 2, 442-4.	1.3	9
22	Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 409-413.	0.6	9
23	Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases. <i>Journal of Neurosurgery</i> , 2022, 137, 563-570.	0.9	9
24	Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e440-e448.	0.7	7
25	A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma. <i>Cancer Biomarkers</i> , 2016, 16, 19-29.	0.8	6
26	Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis. <i>Acta Neurochirurgica</i> , 2022, 164, 459-467.	0.9	6
27	Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis. <i>Frontiers in Bioscience</i> , 2021, 26, 1679-1688.	0.8	6
28	Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance. <i>Translational Lung Cancer Research</i> , 2014, 3, 368-9.	1.3	5
29	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7037.	1.8	5
30	Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy. <i>Lung Cancer</i> , 2019, 138, 52-57.	0.9	3
31	Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	3
32	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	1.2	2
33	Prognostic factors and first-line treatment modalities in nonagenarian patients with lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 439-441.	0.5	1
34	The impact of different brain imaging strategies for initial staging and post-treatment surveillance in patients with EGFR-mutant lung adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21145-e21145.	0.8	0
35	Osimertinib in previously EGFR-TKI treated non-small cell lung cancer (NSCLC) patients without T790M mutation: Real-world evidence.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21631-e21631.	0.8	0